Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 22, 2007, Pages 6070-6074

  Patch, Raymond J ^a   Brandt, Benjamin M ^a   Asgari, Davoud ^a   Baindur, Nand ^a   Chadha, Naresh K ^a   Georgiadis, Taxiarchis ^a   Cheung, Wing S ^a   Petrounia, Ioanna P ^a   Donatelli, Robert R ^a   Chaikin, Margery A ^a   Player, Mark R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

2 Aminoanilides; cFMS; Colony stimulating factor 1 receptor; CSF 1; M CSF

Indexed keywords

2' AMINOANILIDE DERIVATIVE; AMINE; ANILIDE; BENZENE; CFMS TYROSINE KINASE; COLONY STIMULATING FACTOR RECEPTOR; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROPHILICITY; IC 50; MACROPHAGE; MOUSE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; SYNTHESIS;

ANILIDES; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; MACROPHAGES; MOLECULAR STRUCTURE; PIPERIDINES; PROTEIN KINASE INHIBITORS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35148871712     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.057     Document Type: Article

References (21)

1. Sherr C.J. Biochim. Biophys. Acta 948 (1988) 225
2. Pixley F.J., and Stanley E.R. Trends Cell Biol. 14 (2004) 628
3. Sherr C.J., Roussel M.F., and Rettenmier C.W. J. Cell Biochem. 38 (1988) 179
4. Yanni G., Whelan A., Feighery C., and Bresnihan B. Ann. Rheum. Dis. 53 (1994) 39
5. Yang N., Isbel N.M., Nikolic-Paterson D.J., Li Y., Ye R., Atkins R.C., and Lan H.Y. Kidney Int. 54 (1998) 143
6. Isbel N.M., Nikolic-Patterson D.J., Hill P.A., Dowling J., and Atkins R.C. Nephrol. Dial. Transplant. 16 (2001) 1638
7. Hamilton H.A. Trends Immunol. 23 (2002) 403
8. Conway J.G., McDonald B., Parham J., Keith B., Rusnak D.W., Shaw E., Jansen M., Lin P., Payne A., Crosby R.M., Johnson J.H., Frick L., Lin M.-H.J., Depee S., Tadepalli S., Votta B., James I., Fuller K., Chambers T.J., Kull F.C., Chamberlain S.D., and Hutchins J.T. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 16078
9. Campbell I.K., Rich M.J., Bischof R.J., and Hamilton J.A. J. Leukocyte Biol. 68 (2000) 144
10. Cook A.D., Braine E.L., Campbell I.K., Rich M.J., and Hamilton J.A. Arthritis Res. 3 (2001) 293
11. Lawlor K.E., Campbell I.K., Metcalf D., O'Donnell K., van Nieuwenhuijze A., Roberts A.W., and Wicks I.P. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11398
12. Jung R., Le J.Y., Wengenmayer F., Wolf E., and Kramer M. Biomed. Biochim. Acta 44 (1985) 485
13. McCalla D.R. Environ. Mutagen. 5 (1983) 745
14. Schmid A. Tierarztl. Prax. 13 (1985) 471
15. Polymer-bound morpholine (PS-morpholine) was obtained from Sigma-Aldrich Chemical Co.
16. cFMS autophosphorylation assay. Schalk-Hihi C., Ma H.C., Struble G.T., Bayoumy S., Williams R., Devine E., Petrounia I.P., Mezzasalma T., Zeng L., Schubert C., Grasberger B., Springer B.A., and Deckman I.C. J. Biol. Chem. 282 (2007) 4085
17. That this cyclic amine should be aliphatic was determined from the initial screening set data. For example, the N-pyrrolo analogue of 1 was found to be inactive.
18. HEK293 phosphorylation assay. Baumann C.A., Zeng L., Donatelli R.R., and Maroney A.C. J. Biochem. Biophys. Methods 60 (2004) 69
19. Kaye P.M. In: Paulnock D.M. (Ed). Macrophages (2000), Oxford University Press, Oxford 93-113
20. ® software and a four parameter logistics equation.
21. Schubert C., Schalk-Hihi C., Struble G.T., Ma H.C., Petrounia I.P., Brandt B., Deckman I.C., Patch R.J., Player M.R., Spurlino J.C., and Springer B.A. J. Biol. Chem. 282 (2007) 4094 PDB: 2I0Y